OSINT
Allegedly, according to recent findings, these structures from J&J 'vaccine' microscopy by Dr. Zandré Botha are what appear to be microbubbles that can be used as a drug delivery system.
Intechopen
Using Microbubbles as Targeted Drug Delivery to Improve AIDS
No preventive vaccines are available for the treatment of AIDS. To improve therapy, combinational antiretroviral drugs are given; however some patients develop resistance to particular combinational drug. Microbubble-mediated drug delivery technology solves…
3e4e93fb-4e98-4081-9315-16143c2bbd2b.pdf
486.4 KB
Deaths in Children and Young People in England following SARS-CoV-2
infection during the first pandemic year: a national study using linked
mandatory child death reporting data | ResearchSquare (2021)
infection during the first pandemic year: a national study using linked
mandatory child death reporting data | ResearchSquare (2021)
s41586-020-2538-8.pdf
6.9 MB
A perspective on potential antibody-dependent enhancement of SARS-CoV-2 | Nature (2020)
zcd189.pdf
1.6 MB
Brief History and Characterization of Enhanced Respiratory Syncytial
Virus Disease | Clinical and Vaccine Immunology (2015)
Virus Disease | Clinical and Vaccine Immunology (2015)
OSINT
zcd189.pdf
In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease when they became infected with wild-type virus, resulting in the death of two vaccinated toddlers due to the nonprotective antibody response created by the vaccine. This antibody dependant enhancement of disease created immune complex deposits in the lungs triggering an aggressive inflammation response resulting in high fever, bronchopneumonia, and wheezing.
OSINT
s41586-020-2538-8.pdf
"Antibody-dependent enhancement (ADE) of disease is a general concern for the development of vaccines ..."
"... the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology."
"At present, there are no known clinical fndings, immunological assays or biomarkers that can differentiate any severe viral infection from immune-enhanced disease, ..."
"because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies—regardless of what virus is the causative agent—it will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward."
"... the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology."
"At present, there are no known clinical fndings, immunological assays or biomarkers that can differentiate any severe viral infection from immune-enhanced disease, ..."
"because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies—regardless of what virus is the causative agent—it will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward."
Technical_Briefing_20.pdf
2.5 MB
SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 20 | Public Health England 6 August 2021
OSINT
Technical_Briefing_20.pdf
PHE data shows vaccinated are 39% of cases but 64% of deaths
The 20th technical report from Public Health England shows that from 1 February 2021 to 2 August 2021; despite being only 39% (117,115) of the confirmed delta infections, of the 742 deaths from the delta variant, 64% (481) are in the partly or fully vaccinated.
The 20th technical report from Public Health England shows that from 1 February 2021 to 2 August 2021; despite being only 39% (117,115) of the confirmed delta infections, of the 742 deaths from the delta variant, 64% (481) are in the partly or fully vaccinated.
This media is not supported in your browser
VIEW IN TELEGRAM
~4,500% more likely to die from the vaccine than from COVID
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext